BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
Bausch Health Companies Inc. (NYSE:BHC) reported Q2 2026 revenue of $2.85B, up 13% year over year, and GAAP net income attributable to the company of $258M. GAAP diluted EPS was $0.68 and adjusted diluted EPS was $1.26. Adjusted EBITDA was $1.075B. The company raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flows.
How this was made
The 30-second read
Why it matters
The company delivered Q2 2026 revenue growth (reported and organic), higher GAAP and adjusted EPS, and strong operating cash flow, and it raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flows from operations.
Market read
A guidance raise with detailed Q2 financials is a direct catalyst for earnings expectations and valuation multiples.
What to watch
Investors may focus on sustainability of cash flow and net debt reduction, plus how much of growth is driven by specific products like Xifaxan versus broader pipeline/business development.
Background
Bausch Health is a diversified healthcare company with segments including Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Ticker impact
Bausch Health reported Q2 2026 results and raised full-year 2026 revenue, adjusted EBITDA, and adjusted cash flow guidance.
Likely positive near-term bias as guidance raise can re-rate expectations, with follow-through dependent on how investors weigh segment strength and leverage reduction.
The article provides specific Q2 financial datapoints and explicitly states the company is raising full-year guidance, which is a direct catalyst for repricing.
Market effects
Improves sentiment for diversified pharma and specialty pharma peers by signaling demand resilience and cash generation.
International segment commentary (LATAM/EMEA strength, Canada softer) may influence regional expectations for specialty pharma demand.
Guidance raise can modestly affect global investor sentiment toward healthcare balance-sheet de-leveraging stories.
Counterpoint
Guidance could still embed execution risk, and organic growth may be uneven across segments (e.g., Diversified segment flat on an organic basis).
Key entities
- companyBausch Health Companies Inc.
Announced Q2 2026 results and raised full-year 2026 guidance.
- personThomas J. Appio
CEO quoted on performance and financial flexibility.
